Weather variations demonstrated a minimal impact on psoriatic arthritis symptoms at the patient level, according to study findings.

Studies evaluating icotrokina in psoriatic arthritis are set to begin next year, while results from a Phase 2 test in ...

WASHINGTON -- Rheumatoid arthritis (RA) patients who achieved sustained remission had better long-term outcomes than those ...

Many patients with rheumatic diseases refrain from telling their doctors about all physical and emotional symptoms they’re ...

As we previously reported, this August the European Commission granted approval for Celltrion’s STELARA biosimilar, STEQEYMA. Earlier this ...

MoonLake Immunotherapeutics (MLTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday.

One woman’s journey from receiving her diagnosis to finding a treatment that helps manage her chronic skin condition.

MoonLake Immunotherapeutics (MLTX) announced that the first patients have been screened at U.S. trial sites in its global Phase 3 clinical ...

Treatment with IV secukinumab led to rapid improvements in the signs and symptoms of PsA, which were maintained through 52 weeks.

in patients with active psoriatic arthritis (PsA). PsA is a chronic, debilitating and progressive inflammatory condition that ...